STAT

Reporting from the frontiers of health & medicine.
Sign up for any of our newsletters here:

[STAT @statnews]

The Deadliest Drug: STAT's new multipart series on the United States’ drinking problem, and a nation in denial.

https://t.co/sO01FqLgwk

[STAT @statnews]

The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread, according to a new U.S. analysis. https://t.co/i8Ty5GqJod

[STAT @statnews]

An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities. https://t.co/gTso3HQJ4L

[STAT @statnews]

Male puberty is understudied — but when it starts may predict long-term health risks https://t.co/O8eYY2Gjtm

[STAT @statnews]

Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired https://t.co/fIhqkN2U5u

[STAT @statnews]

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines’ pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? https://t.co/ajQWdjPmgd

[STAT @statnews]

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy https://t.co/bUOceoQhzt

[STAT @statnews]

Tiny HHS office tasked with protecting research participants’ safety is running on fumes https://t.co/13gBbhBbK4

[STAT @statnews]

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. https://t.co/BW4WEC4eqf

[STAT @statnews]

"New work requirements are catastrophic for cancer patients." https://t.co/gjiEIZGvNu

[STAT @statnews]

When I deployed to Sierra Leone during the 2014-2016 West Africa Ebola epidemic, I understood the risks. Every physician, nurse, epidemiologist, laboratorian, and aid worker who enters an Ebola outbreak… https://t.co/ViNWmB0BNL

[STAT @statnews]

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news https://t.co/kj0s9HBzLf

[STAT @statnews]

Developers pitch their patient apps as diligent note-takers to keep track of encounters across the health system https://t.co/NSCzQo2K68

[STAT @statnews]

Texas Attorney General Ken Paxton is launching an “investigation” into energy drink company Celsius.

The news comes after a Texas family sued Celsius, alleging that their teen died from an enlarged heart brought on by excessive caffeine consumption. https://t.co/xOUEQUmfvR

[STAT @statnews]

Patient advocates, former agency officials, and many industry players are urging the FDA to pause former commissioner Marty Makary's drug voucher program and reintroduce it through formal rulemaking: https://t.co/V1gPs7tgSS

[Adam Feuerstein ✡️ @adamfeuerstein]

"I got my normal back."

That's how Leanna Stokes, mother of 2 young boys and a person living with metastatic pancreatic cancer, described her life following treatment w/ daraxonrasib.

Listen to our conversation w/ Leanna on this week's Readout LOUD podcast. Well worth your time.

[STAT @statnews]

Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program https://t.co/m3gxh0xGUV

[STAT @statnews]

“I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.” https://t.co/9pl7UIxhLS

[Emily Sweeney @emilysweeney]

Alex Hogan of @statnews asks if he should use his local Somerville accent or his more neutral, professional tone when delivering the news. I vote for Somerville..let the local accent loose! What do you think? Check out his latest STATus Report and let him know in the comments :)
https://t.co/TFbyug0uNr

[STAT @statnews]

Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment. https://t.co/obRgFtVTm0

[STAT @statnews]

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels. https://t.co/3cHPm4ENYE